公开(公告)号：US20250025526A1

公开(公告)日：2025-01-23

申请号：US18899153

申请日：2024-09-27

Applicant: Stealth BioTherapeutics Inc.

Inventor： David Brown ,  Alyssa Handler ,  Laura Kropp ,  Henry Hess

IPC: A61K38/07 ,  A61K31/277 ,  A61P25/28

Abstract: The present disclosure provides a combination therapy for treating, preventing, inhibiting, ameliorating, or delaying the onset of Friedreich's ataxia in a subject in need thereof comprising administering to the subject both elamipretide and omaveloxolone or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, tautomers, hydrates, and/or solvates thereof. The present disclosure further provides an embodiment of a combination product suitable for administration to said subject.

公开(公告)号：US20250009717A1

公开(公告)日：2025-01-09

申请号：US18672743

申请日：2024-05-23

Applicant: Stealth BioTherapeutics Inc.

Inventor： Dennis Keefe ,  Guozhu Zheng ,  Vania Broccoli

IPC: A61K31/4245 ,  A61K31/135 ,  A61K31/197 ,  A61K31/4152 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/5513 ,  A61K38/30 ,  A61P25/28

Abstract: The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondria-targeting peptidomimetic compound, such as (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.

公开(公告)号：US12110345B2

公开(公告)日：2024-10-08

申请号：US18231483

申请日：2023-08-08

Applicant: Stealth BioTherapeutics Inc.

Inventor： Scott M. Duncan

IPC: C30B29/58 ,  C07K5/11

CPC classification number: C07K5/1019 ,  C30B29/58 ,  C07B2200/13

Abstract: Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH2.

公开(公告)号：US20230279051A1

公开(公告)日：2023-09-07

申请号：US17963697

申请日：2022-10-11

Applicant: Stealth BioTherapeutics Inc.

Inventor： D. Travis Wilson

IPC: C07K5/11 ,  A61K38/07 ,  C07K5/107

CPC classification number: C07K5/1019 ,  A61K38/07 ,  C07K5/1016 ,  A61K45/06

Abstract: The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ameliorate the disruption of mitochondrial oxidative phosphorylation in a cell such as that found in a subject suffering from, or predisposed to a mitochondrial disease or disorder. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for a mitochondrial disease or disorder, an effective amount of an aromatic-cationic peptide to subjects in need thereof.

公开(公告)号：US11366104B2

公开(公告)日：2022-06-21

申请号：US16845687

申请日：2020-04-10

Applicant: Stealth BioTherapeutics Inc.

Inventor： D. Travis Wilson

IPC: G01N33/50

Abstract: The present technology provides methods for detecting and diagnosing diseases and conditions characterized by mitochondrial dysfunction using monocytes as an indicator of the dysfunction.

公开(公告)号：US20250057805A1

公开(公告)日：2025-02-20

申请号：US18819188

申请日：2024-08-29

Applicant: Stealth BioTherapeutics Inc.

Inventor： Anthony Abbruscato ,  Alana W. Sullivan ,  Laura Kropp

IPC: A61K31/353 ,  A61K31/138 ,  A61K31/436 ,  A61K31/58 ,  A61K45/06 ,  A61P37/08

Abstract: The present disclosure provides methods for treating, preventing, ameliorating, inhibiting or delaying the onset of injection site reactions associated with the subcutaneous administration of bevemipretide, or a pharmaceutically acceptable salt thereof. The methods may involve administration of inhibitors of the MRGPRX2 receptor and/or inhibitors of mast cell degranulation. In some cases, the methods involve administration of an effective amount of a flavonoid, a coumarin, a phenol, a terpenoid, mometasone furoate, tacrolimus, quercetin, diphenhydramine and/or ice.

公开(公告)号：US20240350577A1

公开(公告)日：2024-10-24

申请号：US18588617

申请日：2024-02-27

Applicant: Stealth BioTherapeutics Inc.

Inventor： D. Travis Wilson

IPC: A61K38/07 ,  A61K31/00 ,  A61K45/06

CPC classification number: A61K38/07 ,  A61K31/00 ,  A61K45/06

Abstract: The disclosure generally describes methods of preventing or treating dominant optic atrophy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates generally to the treatment or prevention of Leber's hereditary optic neuropathy (LHON) or dominant optic atrophy (DOA) in mammals through administration of therapeutically effective amounts of aromatic-cationic peptides to subjects in need thereof. In one aspect, the present disclosure provides a method of treating or preventing dominant optic atrophy in a mammalian subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide.

公开(公告)号：US20240299486A1

公开(公告)日：2024-09-12

申请号：US18666362

申请日：2024-05-16

Applicant: STEALTH BIOTHERAPEUTICS INC.

Inventor： Anthony Abbruscato ,  Alana W. Sullivan ,  Laura Kropp

IPC: A61K38/07 ,  A61K9/00 ,  A61K9/06 ,  A61K31/05 ,  A61K31/352 ,  A61K31/37 ,  A61K31/58

CPC classification number: A61K38/07 ,  A61K9/0019 ,  A61K9/06 ,  A61K31/05 ,  A61K31/352 ,  A61K31/37 ,  A61K31/58

Abstract: The present disclosure provides methods for treating, preventing, ameliorating, inhibiting or delaying the onset of injection site reactions associated with the subcutaneous administration of elamipretide, or a pharmaceutically acceptable salt thereof. The methods may involve administration of inhibitors of the MRGPRX2 receptor and/or inhibitors of mast cell degranulation. In some cases, the methods involve administration of an effective amount of a flavonoid, a coumarin, a phenol, or a terpenoid. Such methods may include applying mometasone furoate, tacrolimus, quercetin, diphenhydramine and/or ice to the elamipretide injection site or intended (injection site to treat, prevent, ameliorate, inhibit or delay the onset of said injection site reactions (ISRs). The present disclosure also provides methods for subcutaneously administering a 60 mg dose of elamipretide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

公开(公告)号：US12037414B2

公开(公告)日：2024-07-16

申请号：US16813380

申请日：2020-03-09

Applicant: STEALTH BIOTHERAPEUTICS INC.

Inventor： Scott Duncan ,  D. Travis Wilson

IPC: C07K1/04 ,  C07K1/02 ,  C07K5/11

CPC classification number: C07K5/1019 ,  C07K1/02 ,  C07K1/04

Abstract: The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2.

公开(公告)号：US12037350B2

公开(公告)日：2024-07-16

申请号：US17221463

申请日：2021-04-02

Applicant: Stealth BioTherapeutics Inc.

Inventor： Dennis Keefe ,  Guozhu Zheng

IPC: C07F7/08 ,  C07C43/23 ,  C07C50/28

CPC classification number: C07F7/081 ,  C07C43/23 ,  C07C50/28

Abstract: The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).